- Based on a thorough reassessment Sesen Bio Inc (NASDAQ:SESN) has decided to voluntarily pause further development in the U.S. of its lead asset, Vicineum, for non-muscle invasive bladder cancer (NMIBC).
- The decision was based on a reassessment of the incremental development timeline and associated costs for an additional Phase 3 clinical trial following recent discussions with the FDA.
- This decision enables Sesen Bio to conserve cash while assessing potential strategic alternatives. Additionally, the company intends to seek a partner to develop Vicineum further.
- Related: Sesen Bio To Conduct Additional Trial For Potential Resubmission Of Vicineum In Bladder Cancer.
- As of June 30, the company had $161.2 million in cash and cash equivalents.
- Vicineum is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A.
- Price Action: SESN shares are down 17.8% at $0.74 during the premarket session on the last check Monday.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.